An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network

SummaryP-glycoprotein (P-gp), an ATP-binding cassette (ABC) transporter, functions as a biological barrier by extruding cytotoxic agents out of cells, resulting in an obstacle in chemotherapeutic treatment of cancer. In order to aid in the development of potential P-gp inhibitors, we constructed a quantitative structure–activity relationship (QSAR) model of flavonoids as P-gp inhibitors based on Bayesian-regularized neural network (BRNN). A dataset of 57 flavonoids collected from a literature binding to the C-terminal nucleotide-binding domain of mouse P-gp was compiled. The predictive ability of the model was assessed using a test set that was independent of the training set, which showed a standard error of prediction of 0.146 ± 0.006 (data scaled from 0 to 1). Meanwhile, two other mathematical tools, back-propagation neural network (BPNN) and partial least squares (PLS) were also attempted to build QSAR models. The BRNN provided slightly better results for the test set compared to BPNN, but the difference was not significant according to F-statistic at p = 0.05. The PLS failed to build a reliable model in the present study. Our study indicates that the BRNN-based in silico model has good potential in facilitating the prediction of P-gp flavonoid inhibitors and might be applied in further drug design.

[1]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[2]  David J. C. MacKay,et al.  A Practical Bayesian Framework for Backpropagation Networks , 1992, Neural Computation.

[3]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  Johann Gasteiger,et al.  Neural networks and genetic algorithms in drug design , 2001 .

[5]  Heekuck Oh,et al.  Neural Networks for Pattern Recognition , 1993, Adv. Comput..

[6]  D K Yu,et al.  The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions , 1999, Journal of clinical pharmacology.

[7]  J. Harborne,et al.  Advances in flavonoid research since 1992. , 2000, Phytochemistry.

[8]  W. H. Moos,et al.  Drug discovery technologies , 1990 .

[9]  Marco Wiering,et al.  Proceedings of the International Joint Conference on Neural Networks, IJCNN 2007, Celebrating 20 years of neural networks, Orlando, Florida, USA, August 12-17, 2007 , 2007, IJCNN.

[10]  D. Signorini,et al.  Neural networks , 1995, The Lancet.

[11]  S. Ekins,et al.  Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.

[12]  F. Burden Using Artificial Neural Networks to Predict Biological Activity from Simple Molecular Structural Considerations , 1996 .

[13]  Pierre Bruneau,et al.  Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets , 2001, J. Chem. Inf. Comput. Sci..

[14]  M B Katan,et al.  Dietary flavonoids: intake, health effects and bioavailability. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[15]  David A Winkler,et al.  Modelling blood-brain barrier partitioning using Bayesian neural nets. , 2004, Journal of molecular graphics & modelling.

[16]  Frank R Burden,et al.  Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network. , 2004, Journal of medicinal chemistry.

[17]  J. Zupan,et al.  Neural Networks in Chemistry , 1993 .

[18]  Bernard Widrow,et al.  Improving the learning speed of 2-layer neural networks by choosing initial values of the adaptive weights , 1990, 1990 IJCNN International Joint Conference on Neural Networks.

[19]  M C Willingham,et al.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[21]  Shuzhong Zhang,et al.  Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport , 2003, Journal of Pharmacology and Experimental Therapeutics.

[22]  Yan Li,et al.  Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis , 2005 .

[23]  I K Pajeva,et al.  Structure-activity relationships of multidrug resistance reversers. , 2001, Current medicinal chemistry.

[24]  Aalt Bast,et al.  Comprehensive medicinal chemistry , 1991 .

[25]  L. Bain,et al.  Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. , 1997, Environmental health perspectives.

[26]  Mohammad Bagher Menhaj,et al.  Training feedforward networks with the Marquardt algorithm , 1994, IEEE Trans. Neural Networks.

[27]  David J. C. MacKay,et al.  Bayesian Interpolation , 1992, Neural Computation.

[28]  Manuela Pavan,et al.  DRAGON SOFTWARE: AN EASY APPROACH TO MOLECULAR DESCRIPTOR CALCULATIONS , 2006 .

[29]  Y. Martin,et al.  Quantitative drug design , 1978 .

[30]  F. Burden,et al.  Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.

[31]  Bernard De Baets,et al.  Feature subset selection for splice site prediction , 2002, ECCB.

[32]  A. Safa,et al.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. , 2004, Current medicinal chemistry. Anti-cancer agents.

[33]  Geoffrey E. Hinton,et al.  Bayesian Learning for Neural Networks , 1995 .

[34]  G. Lewin,et al.  Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships. , 1999, Journal of medicinal chemistry.

[35]  David Mackay,et al.  Probable networks and plausible predictions - a review of practical Bayesian methods for supervised neural networks , 1995 .

[36]  A. Höskuldsson PLS regression methods , 1988 .

[37]  V. Ling,et al.  Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. , 1997, Biochemical pharmacology.

[38]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Rumi,et al.  Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target , 2004, Cancer Chemotherapy and Pharmacology.

[40]  H. M. Pinedo,et al.  Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. , 1993, British Journal of Cancer.

[41]  Yitzhak Mendelson,et al.  Multivariate Determination of Glucose in Whole Blood Using Partial Least-Squares and Artificial Neural Networks Based on Mid-Infrared Spectroscopy , 1993 .

[42]  William D. Penny,et al.  An empirical evaluation of Bayesian sampling with hybrid Monte Carlo for training neural network classifiers , 1999, Neural Networks.

[43]  김삼묘,et al.  “Bioinformatics” 특집을 내면서 , 2000 .

[44]  Frank R. Burden,et al.  Use of Automatic Relevance Determination in QSAR Studies Using Bayesian Neural Networks , 2000, J. Chem. Inf. Comput. Sci..

[45]  Alan F. Murray,et al.  IEEE International Conference on Neural Networks , 1997 .

[46]  A. Goffeau,et al.  Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters , 2002, Cellular and Molecular Life Sciences CMLS.

[47]  F. Cervelli,et al.  Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. , 1995, Life sciences.